Aduro BioTech, Inc. is an immunotherapy company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ADRO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Aduro BioTech could be a solid choice for investors.
Current Quarter Estimates for ADRO
In the past 30 days, one estimate has gone higher for Aduro BioTech while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 37 cents a share 30 days ago, to a loss of 33 today, a move of 10.8%.
Current Year Estimates for ADRO
Meanwhile, Aduro BioTech’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.46 per share 30 days ago to a loss of $1.31 per share today, an increase of 10.3%.
Bottom Line
The stock has also started to move higher lately, adding 8.04% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Image: Bigstock
Can Aduro BioTech (ADRO) Run Higher on Strong Earnings Estimate Revisions?
Aduro BioTech, Inc. is an immunotherapy company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ADRO’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Aduro BioTech could be a solid choice for investors.
Current Quarter Estimates for ADRO
In the past 30 days, one estimate has gone higher for Aduro BioTech while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 37 cents a share 30 days ago, to a loss of 33 today, a move of 10.8%.
Current Year Estimates for ADRO
Meanwhile, Aduro BioTech’s current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.46 per share 30 days ago to a loss of $1.31 per share today, an increase of 10.3%.
Aduro Biotech, Inc. Price and Consensus
Aduro Biotech, Inc. Price and Consensus | Aduro Biotech, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 8.04% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>